2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidinis CAS 161599-46-8 Puritas ≥99.0% Capecitabine Intermedia Factory

Description:

Nomen: 2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine

CAS: 161599-46-8

Aspectus: albus vel flavescens Crystallinus pulveris

Dic: ≥99.0%Puritas: ≥99.0% (HPLC)

Capecitabin (CAS: 154361-50-9)

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Commercial Supple Capecitabine Related Intermedia:
5-Fluorocytosine CAS: 2022-85-7
2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidinis CAS: 161599-46-8
1,2,3 Tri-O-acetyl-5-deoxy-β-D-ribofuranosum CAS: 62211-93-2
Capecitabine CAS: 154361-50-9

Chemical Properties:

Nomen	2', 3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine
CAS Number	161599-46-8
CATTUS Number	RF-PI176
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C13H16FN3O6
M. Pondus	329.28
Conditio vitare	Calor Sensitiva
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Crystallinus pulver albus vel flavescens
una immunditia	≤0.50%
Totalis immunditias	≤1.0%
Liquescens punctum	178.0~ 193.0℃
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.10%
Humor (KF)	≤1.0%
Assay	≥99.0%
Puritas / Analysis Methodus	≥99.0% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	Capecitabin (CAS: 154361-50-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.

commoda:

FAQ:

Applicatio:

Capecitabine (CAS: 154361-50-9) est nova forma medicamenti pyrimidinis oris fluorinated.Capecitabinum a Roche Pharmaceuticis explicatum est, et nomen eius mercatorum Xeloda est.Capecitabinum vivo in 5. FU mutare potest, medicamentum anti-metabolizim fluorinum pyrimidinem deoxynucleoside carbamatum, qui scuta cellas cancri ad divisionem cellam inhibent et RNA et interdum synthesim perturbant.Effectus eius signanter ligantur cum plano TP enzyme expressionis in textu neoplastico et DPD enzyme in expressione vivo.Idoneum est curationi ulteriori provectioris primae vel metastaticae cancer pectoris aegros qui paclitaxel vel anthracyclinis antibioticis non responderunt.Ut anticancer medicamento, plerumque tractare cancrum pectus primarium vel metastaticum provectus est, tum in curatione de cancro cellulae pulmone non parva, cancer pancreaticus, cancer vesicae, cancer rectalis, cancer colon, cancer gastricus, et alii tumores solidi. .